The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Featured:
Although many different drugs are available to treat multiple myeloma (MM), high-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) remains the gold standard, and use of this treatment approach has increased in Europe, especially as a second- and later-line option.1
Studies assessing various transplant intensification strategies to improve disease control have been conducted, however, no clear consensus on their use has emerged. To help guide clinicians in choosing between different upfront transplant strategies in MM (e.g. single auto-HSCT, tandem auto-HSCT, and auto-allogeneic HSCT [auto-allo HSCT]), the Chronic Malignancies Working Party (CMWP) of the European Society for Blood and Bone Marrow Transplantation (EBMT) has evaluated the outcomes from a large cohort of almost 25,000 patients with MM enrolled into the EBMT Registry who received their first auto-HSCT in EBMT centers. The study results were presented at the 61st American Society of Hematology Meeting & Exposition, Orlando, US, by Stefan Schönland from the University Clinic Heidelberg, Heidelberg, DE.2
To watch a recent interview with Mohamad Mohty from Saint-Antoine Hospital and Sorbonne University, Paris, FR, on the future role of autologous transplant in the treatment of MM, scroll to the end of this article, or click here.
Table 1. Patient characteristics
Allo, allogeneic; Auto, autologous; CR, complete response; HSCT, hematopoietic stem cell transplantation; PR, partial response |
|||
|
Total group (N= 24,936) |
Auto-auto-HSCT (n= 3,683) |
Auto-allo-HSCT (n= 878) |
---|---|---|---|
Age at first auto-HSCT, years, median (range) |
57(18.1–65) |
56.7 (23.4–65) |
51.7 (18.9–65) |
18–50 years |
20% |
21% |
42% |
50–60 years |
48% |
49% |
47% |
60–65 years |
32% |
30% |
11% |
Male |
58% |
60% |
63% |
Time from diagnosis to first auto-HSCT <12 months |
78% |
81% |
86% |
Status at first auto-HSCT: CR/PR |
18%/69% |
9%/72% |
8%/67% |
Year of first auto-HSCT |
|
|
|
2002–2006 |
33% |
50% |
56% |
2007–2011 |
45% |
35% |
34% |
2012–2015 |
22% |
15% |
10% |
Median time from first auto-HSCT to second transplant, months |
– |
3.6 (0.5–9) |
3.9 (1.1–9) |
Status at second transplant: CR/PR |
– |
18%/69% |
19%/66% |
Table 2. Predictors of PFS and OS after first auto-HSCT
CR, complete response; HR, hazard ratio |
||
|
HR (95% CI) |
p value |
---|---|---|
OS dynamic prediction |
||
Age (+ 1 year) |
1.02 (1.02–1.03) |
< 0.001 |
Calendar year (+ 1 year) |
0.98 (0.97–0.98) |
< 0.001 |
No CR status at 1st transplant |
1.08 (1.01–1.16) |
0.021 |
PFS dynamic prediction |
||
Age (+ 1 year) |
1.01 (1.01–1.01) |
< 0.001 |
Calendar year (+ 1 year) |
1 (0.99–1.00) |
0.683 |
No CR status at 1st transplant |
1.29 (1.22–1.36) |
< 0.001 |
This study demonstrated, in a large cohort of patients who had undergone auto- and allo-HSCT as first-line treatment for MM, that a younger age and having a CR at first transplant were positive prognostic factors for PFS and OS. The study also demonstrated that tandem auto-allo-HSCT was associated with the best long-term disease control, however, the PFS benefits observed only translated into a small OS benefit, even when the analysis was restricted to patients who did not have a CR at the time of their first auto-HSCT.
The authors cautioned that, although early mortality after allogeneic transplantation has decreased in the last decade, current mortality risk and late morbidity such as chronic graft-versus-host disease should be balanced against any improved long-term survival.
References